Endometrial glandular dysplasia with frequent p53 gene mutation

A genetic evidence supporting its precancer nature for endometrial serous carcinoma

Lin Jia, Yongjuan Liu, Xiaofang Yi, Alexander Miron, Christopher P. Crum, Beihua Kong, Wenxin - Zheng

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

Purpose: Endometrial glandular dysplasia (EmGD) has been recently proposed to be a putative precursor to endometrial serous carcinoma (ESC). The purpose of this study is to determine if EmGD is genetically linked to ESC and if it can be used for early detection. Experimental Design:The tumor suppressor p53 gene was sequenced from serial samples of benign and neoplastic endometria with serous differentiation. The study group contained 15 neoplastic uteri and the control group had 12 age-matched benign uteri. A total of 139 informative samples were obtained, including 55 resting endometrium, 37 EmGD, 25 serous endometrial intraepithelial carcinoma (EIC), and 22 ESC. At least one representative section from each uterus was used for p53 immunohistochemical staining to correlate p53 overexpression with gene mutation status. Results: The mutations of p53 were detected in 0%, 43%, 72%, and 96% in resting endometrium, EmGD, serous EIC, and ESC, respectively. More than 50% of the neoplastic uteri showed at least one identical p53 gene mutant among lesions of EmGD, serous EIC, and/or ESC. The majority of lesions showed overexpression of p53 protein, which was significantly correlated with p53 gene mutation (P < 0.01). Conclusions: This genetic evidence strongly supports that EmGD represents the precancer of ESC or serous EIC. Mutation of p53 gene is probably one of the most important factors to initiate the endometrial serous carcinogenesis. Correct identification of EmGD will provide us an opportunity of early diagnosis and a potentially effective therapeutic modality to control ESC.

Original languageEnglish (US)
Pages (from-to)2263-2269
Number of pages7
JournalClinical Cancer Research
Volume14
Issue number8
DOIs
StatePublished - Apr 15 2008

Fingerprint

p53 Genes
Endometrial Neoplasms
Mutation
Carcinoma in Situ
Uterus
Endometrium
Tumor Suppressor Genes
Early Diagnosis
Carcinogenesis
Research Design
Staining and Labeling
Control Groups

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Endometrial glandular dysplasia with frequent p53 gene mutation : A genetic evidence supporting its precancer nature for endometrial serous carcinoma. / Jia, Lin; Liu, Yongjuan; Yi, Xiaofang; Miron, Alexander; Crum, Christopher P.; Kong, Beihua; Zheng, Wenxin -.

In: Clinical Cancer Research, Vol. 14, No. 8, 15.04.2008, p. 2263-2269.

Research output: Contribution to journalArticle

Jia, Lin ; Liu, Yongjuan ; Yi, Xiaofang ; Miron, Alexander ; Crum, Christopher P. ; Kong, Beihua ; Zheng, Wenxin -. / Endometrial glandular dysplasia with frequent p53 gene mutation : A genetic evidence supporting its precancer nature for endometrial serous carcinoma. In: Clinical Cancer Research. 2008 ; Vol. 14, No. 8. pp. 2263-2269.
@article{ba9288360efe4c838f67be8509fd9a6e,
title = "Endometrial glandular dysplasia with frequent p53 gene mutation: A genetic evidence supporting its precancer nature for endometrial serous carcinoma",
abstract = "Purpose: Endometrial glandular dysplasia (EmGD) has been recently proposed to be a putative precursor to endometrial serous carcinoma (ESC). The purpose of this study is to determine if EmGD is genetically linked to ESC and if it can be used for early detection. Experimental Design:The tumor suppressor p53 gene was sequenced from serial samples of benign and neoplastic endometria with serous differentiation. The study group contained 15 neoplastic uteri and the control group had 12 age-matched benign uteri. A total of 139 informative samples were obtained, including 55 resting endometrium, 37 EmGD, 25 serous endometrial intraepithelial carcinoma (EIC), and 22 ESC. At least one representative section from each uterus was used for p53 immunohistochemical staining to correlate p53 overexpression with gene mutation status. Results: The mutations of p53 were detected in 0{\%}, 43{\%}, 72{\%}, and 96{\%} in resting endometrium, EmGD, serous EIC, and ESC, respectively. More than 50{\%} of the neoplastic uteri showed at least one identical p53 gene mutant among lesions of EmGD, serous EIC, and/or ESC. The majority of lesions showed overexpression of p53 protein, which was significantly correlated with p53 gene mutation (P < 0.01). Conclusions: This genetic evidence strongly supports that EmGD represents the precancer of ESC or serous EIC. Mutation of p53 gene is probably one of the most important factors to initiate the endometrial serous carcinogenesis. Correct identification of EmGD will provide us an opportunity of early diagnosis and a potentially effective therapeutic modality to control ESC.",
author = "Lin Jia and Yongjuan Liu and Xiaofang Yi and Alexander Miron and Crum, {Christopher P.} and Beihua Kong and Zheng, {Wenxin -}",
year = "2008",
month = "4",
day = "15",
doi = "10.1158/1078-0432.CCR-07-4837",
language = "English (US)",
volume = "14",
pages = "2263--2269",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Endometrial glandular dysplasia with frequent p53 gene mutation

T2 - A genetic evidence supporting its precancer nature for endometrial serous carcinoma

AU - Jia, Lin

AU - Liu, Yongjuan

AU - Yi, Xiaofang

AU - Miron, Alexander

AU - Crum, Christopher P.

AU - Kong, Beihua

AU - Zheng, Wenxin -

PY - 2008/4/15

Y1 - 2008/4/15

N2 - Purpose: Endometrial glandular dysplasia (EmGD) has been recently proposed to be a putative precursor to endometrial serous carcinoma (ESC). The purpose of this study is to determine if EmGD is genetically linked to ESC and if it can be used for early detection. Experimental Design:The tumor suppressor p53 gene was sequenced from serial samples of benign and neoplastic endometria with serous differentiation. The study group contained 15 neoplastic uteri and the control group had 12 age-matched benign uteri. A total of 139 informative samples were obtained, including 55 resting endometrium, 37 EmGD, 25 serous endometrial intraepithelial carcinoma (EIC), and 22 ESC. At least one representative section from each uterus was used for p53 immunohistochemical staining to correlate p53 overexpression with gene mutation status. Results: The mutations of p53 were detected in 0%, 43%, 72%, and 96% in resting endometrium, EmGD, serous EIC, and ESC, respectively. More than 50% of the neoplastic uteri showed at least one identical p53 gene mutant among lesions of EmGD, serous EIC, and/or ESC. The majority of lesions showed overexpression of p53 protein, which was significantly correlated with p53 gene mutation (P < 0.01). Conclusions: This genetic evidence strongly supports that EmGD represents the precancer of ESC or serous EIC. Mutation of p53 gene is probably one of the most important factors to initiate the endometrial serous carcinogenesis. Correct identification of EmGD will provide us an opportunity of early diagnosis and a potentially effective therapeutic modality to control ESC.

AB - Purpose: Endometrial glandular dysplasia (EmGD) has been recently proposed to be a putative precursor to endometrial serous carcinoma (ESC). The purpose of this study is to determine if EmGD is genetically linked to ESC and if it can be used for early detection. Experimental Design:The tumor suppressor p53 gene was sequenced from serial samples of benign and neoplastic endometria with serous differentiation. The study group contained 15 neoplastic uteri and the control group had 12 age-matched benign uteri. A total of 139 informative samples were obtained, including 55 resting endometrium, 37 EmGD, 25 serous endometrial intraepithelial carcinoma (EIC), and 22 ESC. At least one representative section from each uterus was used for p53 immunohistochemical staining to correlate p53 overexpression with gene mutation status. Results: The mutations of p53 were detected in 0%, 43%, 72%, and 96% in resting endometrium, EmGD, serous EIC, and ESC, respectively. More than 50% of the neoplastic uteri showed at least one identical p53 gene mutant among lesions of EmGD, serous EIC, and/or ESC. The majority of lesions showed overexpression of p53 protein, which was significantly correlated with p53 gene mutation (P < 0.01). Conclusions: This genetic evidence strongly supports that EmGD represents the precancer of ESC or serous EIC. Mutation of p53 gene is probably one of the most important factors to initiate the endometrial serous carcinogenesis. Correct identification of EmGD will provide us an opportunity of early diagnosis and a potentially effective therapeutic modality to control ESC.

UR - http://www.scopus.com/inward/record.url?scp=42249113463&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42249113463&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-07-4837

DO - 10.1158/1078-0432.CCR-07-4837

M3 - Article

VL - 14

SP - 2263

EP - 2269

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 8

ER -